on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation
On June 5, 2024, OSE Immunotherapeutics and the University Hospital Center of Nantes revealed at the American Transplant Congress in Philadelphia a positive evaluation of the Phase 1/2 clinical trial on FR104/VEL-101 immunotherapy. This innovative treatment was administered to patients who had undergone kidney transplantation.
Gilles Blancho, Director of the Institute of Transplantation Urology-Nephrology, highlighted the promising results of this study, particularly on the safety and effectiveness of FR104/VEL-101 after one year of follow-up. Primarily, no acute rejection was observed among the patients studied.
Additionally, OSE partner Veloxis Pharmaceuticals described the safety and pharmacodynamic results of the subcutaneously administered immunotherapy in a separate communication.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news